Alembic Pharmaceuticals Future Growth

Future criteria checks 3/6

Alembic Pharmaceuticals is forecast to grow earnings and revenue by 19.1% and 10.8% per annum respectively. EPS is expected to grow by 18.2% per annum. Return on equity is forecast to be 15.9% in 3 years.

Key information

19.1%

Earnings growth rate

18.2%

EPS growth rate

Pharmaceuticals earnings growth	18.1%
Revenue growth rate	10.8%
Future return on equity	15.9%
Analyst coverage	Good
Last updated	30 Sep 2024

Recent future growth updates

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 13

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Recent updates

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Sep 25

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Sep 03

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 13

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Jul 20

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Jun 03

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

May 11

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 08

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Jan 21

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jan 04

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now

Nov 05

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden

Aug 10

Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Jul 20

We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt

May 05

Earnings and Revenue Growth Forecasts

NSEI:APLLTD - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	85,062	10,934	8,944	N/A	4
3/31/2026	76,479	8,613	6,855	N/A	11
3/31/2025	68,320	6,951	5,360	N/A	11
6/30/2024	63,042	6,299	N/A	N/A	N/A
3/31/2024	62,286	6,158	4,757	8,032	N/A
12/31/2023	61,181	5,902	N/A	N/A	N/A
9/30/2023	59,966	5,317	2,042	6,027	N/A
6/30/2023	58,766	5,285	N/A	N/A	N/A
3/31/2023	56,526	3,420	2,805	7,240	N/A
12/31/2022	56,619	2,113	N/A	N/A	N/A
9/30/2022	54,246	2,662	2,893	6,751	N/A
6/30/2022	52,419	3,153	N/A	N/A	N/A
3/31/2022	53,058	5,209	1,267	5,524	N/A
12/31/2021	51,704	7,609	N/A	N/A	N/A
9/30/2021	52,131	8,771	1,767	8,309	N/A
6/30/2021	53,778	10,412	N/A	N/A	N/A
3/31/2021	53,931	11,465	8,039	14,634	N/A
12/31/2020	53,196	11,521	N/A	N/A	N/A
9/30/2020	52,144	10,937	6,209	12,378	N/A
6/30/2020	49,982	10,066	N/A	N/A	N/A
3/31/2020	46,058	8,288	-2,858	4,491	N/A
12/31/2019	43,259	7,282	N/A	N/A	N/A
9/30/2019	41,349	6,638	482	7,967	N/A
6/30/2019	40,211	6,176	N/A	N/A	N/A
3/31/2019	39,347	5,844	476	8,120	N/A
12/31/2018	38,604	5,542	N/A	N/A	N/A
9/30/2018	36,823	5,149	N/A	N/A	N/A
6/30/2018	33,445	4,364	N/A	N/A	N/A
3/31/2018	31,302	4,126	N/A	3,124	N/A
12/31/2017	29,894	4,119	N/A	N/A	N/A
9/30/2017	29,264	3,678	N/A	N/A	N/A
6/30/2017	30,165	3,661	N/A	N/A	N/A
3/31/2017	31,052	4,032	N/A	3,286	N/A
12/31/2016	30,130	3,999	N/A	N/A	N/A
9/30/2016	31,584	5,828	N/A	N/A	N/A
6/30/2016	32,942	7,515	N/A	N/A	N/A
3/31/2016	31,232	7,200	N/A	9,477	N/A
12/31/2015	30,185	6,986	N/A	N/A	N/A
9/30/2015	26,086	4,998	N/A	N/A	N/A
6/30/2015	21,469	2,881	N/A	N/A	N/A
3/31/2015	20,579	2,829	N/A	1,718	N/A
12/31/2014	20,167	2,739	N/A	N/A	N/A
9/30/2014	19,906	2,692	N/A	N/A	N/A
6/30/2014	19,303	2,535	N/A	N/A	N/A
3/31/2014	18,642	2,355	N/A	2,400	N/A
12/31/2013	17,770	2,179	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: APLLTD's forecast earnings growth (19.1% per year) is above the savings rate (6.7%).

Earnings vs Market: APLLTD's earnings (19.1% per year) are forecast to grow faster than the Indian market (17.2% per year).

High Growth Earnings: APLLTD's earnings are forecast to grow, but not significantly.

Revenue vs Market: APLLTD's revenue (10.8% per year) is forecast to grow faster than the Indian market (10.1% per year).

High Growth Revenue: APLLTD's revenue (10.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: APLLTD's Return on Equity is forecast to be low in 3 years time (15.9%).

Alembic Pharmaceuticals Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target increased by 7.2% to ₹1,056

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Recent updates

Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price

Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations

Investor sentiment improves as stock rises 17%

Price target increased by 7.2% to ₹1,056

Now 25% overvalued after recent price rise

Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12%

Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head ­ Legal

Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg

Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher

Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial

Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07%

Upcoming dividend of ₹11.00 per share

Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg

Now 21% overvalued

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Dividend increased to ₹11.00

Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024

Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business)

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly

Now 20% overvalued

Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?

Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023)

Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals

Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024

Price target increased by 8.4% to ₹933

Consensus EPS estimates increase by 14%

Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target increased by 7.4% to ₹827

Third quarter 2024 earnings: Revenues in line with analyst expectations

Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%

Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024

Investor sentiment improves as stock rises 17%

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals

Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited Announces Management Changes

Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023

Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly

Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy

Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel

Price target increased by 10% to ₹659

First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023)

Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023

Upcoming dividend of ₹8.00 per share at 1.2% yield

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly

Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director

A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)

Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?

Consensus EPS estimates fall by 19%

Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022)

Consensus EPS estimates fall by 11%

Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes

Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg

Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration

Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05%

Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w

Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg

Consensus forecasts updated

Insufficient new directors

Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal